Assertio Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Assertio Holdings, Inc.
Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.
A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.
Public Company Edition: Private Galderma raised $1bn but said its next likely financing will be an IPO. Also, Azitra went public while Turnstone, Apogee and Sagimet initiated the process; Sutro signed a royalty deal for up to $390m; and despite a follow-on offering mini-surge, cost cuts continue.
The 2023 MedTech Forum attracted record interest from industry delegates in Europe and beyond. Two days of public sessions included the popular “CEOs No Filter” roundtables, where senior sector representatives were given carte blanche to appraise the state of Europe’s industry.
- Other Names / Subsidiaries
- Depomed, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.